Autoimmune enteropathy

Last updated
Autoimmune enteropathy
Other namesSevere immune-mediated enteropathy, Immune-mediated protracted diarrhea of infancy
Villous blunting in endoscopic biopsy.png
Histological evidence of enteropathy (inflammatory infiltrate, villus blunting) seen in this intestinal biopsy from a child with malnutrition.
Specialty Immunology Gastroenterology
Symptoms Diarrhea, and autoimmune damage to the intestinal mucosa. [1]
Complications Electrolyte imbalances, malabsorption, and failure to thrive. [2]
Usual onsetFirst six months of life. [3]
DurationLifelong [4]
Diagnostic method histological changes, serologic testing, and clinical signs and symptoms. [5]
Differential diagnosis Graft-versus-host disease, Crohn's disease, celiac disease and lactose intolerance. [6]
Treatment Parenteral nutrition and corticosteroids. [7]
Prognosis 30% mortality rate without treatment. [8]
Frequency<1 in 100,000 infants. [1]

Autoimmune enteropathy is a rare autoimmune disorder characterized by weight loss from malabsorption, severe and protracted diarrhea, and autoimmune damage to the intestinal mucosa. [1] Autoimmune enteropathy typically occurs in infants and younger children however, adult cases have been reported in literature. [9] Autoimmune enteropathy was first described by Walker-Smith et al. in 1982. [10]

Contents

The mechanisms of autoimmune enteropathy isn't well known but dysfunction or deficiency of CD25+CD4+ regulatory T cells may play a role. [11] Numerous other illnesses and syndromes are linked to autoimmune enteropathy, the most prominent being Autoimmune polyendocrine syndrome type 1 and immune dysregulation polyendocrinopathy enteropathy X-linked (IPEX) syndrome. [5]

Clinical symptoms, laboratory results, and the histological characteristics of a small bowel biopsy are used to make the diagnosis. [5] These patients typically don't respond to diet modification and often require immune-suppressants and sometimes require total parenteral nutrition. [12] The prevalence of autoimmune enteropathy is estimated to be less than 1 in 100,000 infants [1]

The prognosis of autoimmune enteropathy varies and depends on systemic manifestations, the severity of symptoms, and the degree of gastrointestinal involvement. [13] Children suffering from autoimmune enteropathy are frequently vulnerable to systemic and local infections pertaining to immunotherapy, the intestinal and skin barriers, and malnourishment. [14]

Signs and symptoms

Autoimmune enteropathy usually presents within the first six months of life. Symptoms are typically seen by two to four weeks of age. [3] The hallmark feature of autoimmune enteropathy is severe high-output diarrhea. As a result, patients may develop significant electrolyte abnormalities, malabsorption, and growth failure. [2] More than 60% of cases have an estimated average stool output that is extremely high upon the time of diagnosis. [15]

Multisystem manifestations may include renal, endocrine, [7] hematologic, [16] [17] musculoskeletal system, pulmonary, [1] and liver involvement. [18] Documented conditions include nephritic and nephrotic syndrome, hypothyroidism due to interstitial fibrosis, periportal fibrosis, interstitial pneumopathy, dermatitis/atopic eczema, [7] autoimmune hemolytic anemia, [17] autoimmune hepatitis, chronic pancreatitis, [18] and rheumatoid arthritis. [19] There has also been multiple reports of thymoma presenting with autoimmune enteropathy. [20] Those with autoimmune enteropathy may have systematic autoimmune diseases such as APECED or IPEX. [1] Up to 83% of those with autoimmune enteropathy have one or more autoimmune disorders. These systematic manifestations may occur as a part of a syndrome or in isolation. [3]

Causes

While the degree of gastrointestinal involvement differs in syndromic forms, autoimmune enteropathy frequently occurs in conjunction with a systemic syndrome. [5] The two primary syndromes are autoimmune polyendocrine syndrome type 1 (APS-1) and immunodysregulation polyendocrinopathy enteropathy X-linked (IPEX) syndrome. [21] With 1 in 1.6 million cases of IPEX and 1 in 80,000–130,000 cases of APS-1, both conditions are extremely rare. [22] Certain populations, such as Finnish and Iranian Jews, have higher rates of APS-1 prevalence. [23]

IPEX mainly affects males and is an X-linked recessive condition caused by mutations causing loss of function in the FOXP3 gene found on the X chromosome. [24] The Scurfin protein, which regulates the development of CD4+CD25+ regulatory T cells, is encoded by FOXP3. [25] DNA-binding domain defects in IPEX are caused by mutations in the FOXP3 gene. [26] This disrupts regulatory T cells' regular function, triggering aberrant immune reactions that cause autoimmune symptoms like enteropathy. [27] As of 2018 over 70 mutations of the FOXP3 gene have been identified. [28] The relationship between the phenotypic presentation and specific genotypes is unclear. [29] Clinical manifestations of IPEX syndrome include eczema, endocrine disorders, and autoimmune enteropathy. [27] The most prevalent endocrine disorder is type one diabetes however, adrenal insufficiency and thyroiditis are also common. [30] After one month of age, the most frequent gastrointestinal symptoms are diarrhea as well as failure to thrive. [31] Other clinical features include alopecia, nephropathy, and autoimmune hemolytic anemia. [32]

Patients are classified as "IPEX-like" if they exhibit IPEX-like characteristics but lack the FOXP3 mutation. IPEX-like disorders can have a range of mutations in CD25, CTLA-4, STAT5B, ITCH, LRBA, and STAT1. [30] These patients present with similar clinical manifestations to those observed in IPEX, and numerous mutations lead to abnormalities in the production or function of regulatory T cells. [33]

CD25 deficiency is due to mutations in the IL2Rα gene and is inherited in an autosomal recessive pattern. As a result, the IL-2 receptor is expressed abnormally. [34] Along with autoimmune enteropathy, patients often have other complications such as cytomegalovirus pneumonitis. [35]

LRBA deficiency is caused by mutations to the LRBA gene, which serves an immunomodulatory function on CTLA4. As an immune system checkpoint, CTLA-4 prevents the growth and activation of self-reactive T cells and promotes peripheral tolerance. [36] LRBA deficiency is inherited autosomal recessively and manifests as lymphoproliferation, enteropathy, recurrent infections, and other features of immune dysregulation. [37] LRBA deficiency is most likely due to B cell activation. Laboratory studies often show hypogammaglobulinemia. Gastrointestinal and pulmonary involvement are common. [38]

Both LRBA deficiency and CTLA-4 haploinsufficiency have a significant overlap in that they can cause recurrent infections and immune dysregulation. Because individuals with LRBA deficiency usually have lower levels of CTLA-4 than those with CTLA-4 haploinsufficiency, the condition frequently presents earlier in life. [39] CTLA-4 haploinsufficiency results in abnormal regulatory T cell function and T cell proliferation, which leads to immunodeficiency and autoimmunity traits. [40] Those with CTLA-4 haploinsufficiency with autoimmune infiltration present with frequent infections, cytopenia, and lymphoproliferation. [41] Additionally, patients can present with symptoms associated with autoimmune enteropathy and autoimmune lymphoproliferative syndrome. [42]

"IPEX-like disorders" can also be caused by mutations in the STAT genes, particularly STAT5B and STAT1. Because STAT5B is involved in the formation of regulatory T cells, mutations in this gene are likely to cause abnormal T lymphocyte proliferation. [43] Those with STAT5B mutations present with pulmonary disease, immunodeficiency, and growth failure. [44]

ITCH mutations can lead to low immune tolerance and present as developmental delay, chronic lung disease, and failure to thrive. [45]

Autoimmune polyendocrine syndrome type 1 (APS-1) is caused by mutations in the AIRE gene located on chromosome 21 and is an autosomal recessive condition. More than 100 mutations of AIRE gene have been recorded. [46] The classic triad of symptoms in APS-1 is hypoparathyroidism, adrenal insufficiency, and mucocutaneous candidiasis. The majority of APS-1 patients start showing symptoms early in childhood and gradually get worse as they get older. Usually, the first symptom to appear is candidiasis, which usually affects the nails or oral cavity. Adrenal insufficiency and hypoparathyroidism often follow, usually manifesting between the ages of 5 and 15. [23] Other symptoms of APS-1 include thyroid disease, autoimmune hepatitis, type one diabetes, keratitis, alopecia, gastritis, hypogonadism, and vitiligo. [47]

Diagnosis

Autoimmune enteropathy is diagnosed by a combination of histological changes on small bowel biopsy, serologic testing, and clinical signs and symptoms. Laboratory findings such as intestinal epithelial autoantibodies aid in confirming the diagnosis. [5]

The original diagnostic criteria of autoimmune enteropathy included intractable diarrhea that showed no improvement with diet modifications, no known immunodeficiency, and villous atrophy of the small intestine. [48] More recent studies of adults with autoimmune enteropathy expanded the criteria to include prolonged diarrhea (lasting longer than six weeks) accompanied by malabsorption, diminished intraepithelial lymphocytosis, deep crypt lymphocytosis, increased crypt apoptotic bodies, and the exclusion of other causes of villous atrophy; each of the symptoms listed above is required for a diagnosis. [12]

The most common site of autoimmune enteropathy is the duodenum however, autoimmune enteropathy may also affect other parts of the gastrointestinal tract. Visually, endoscopy may be normal, abnormal findings include ulcerations and mucosal hyperemia. [49] Histopathological features include small bowel villous changes such as atrophy and blunting, typically prominent in the proximal bowel. [12] Occasionally crypt abscesses are also seen. [50] The crypt epithelium may contain apoptotic bodies and lymphocytic infiltration, with comparatively little surface lymphocytosis (less than 40 lymphocytes per 100 epithelial cells). [51] Furthermore, the intestinal mucosa contains CD4-CD8 T lymphocytes and macrophages; goblet and Paneth cells may not be present. [52] On crypt enterocytes, there is an increase in HLA class II molecular expression. [1]

With the possible exception of prominent mesenteric lymph nodes, which may be detected in up to 40% of cases, Abdominal Imaging is typically unremarkable. [9] An important diagnostic technique for determining the autoimmune enteropathy diagnosis is wireless capsule endoscopy. [53] In about 47% of patients with autoimmune enteropathy, capsule endoscopy typically detects small intestinal abnormalities, mostly in the form of scalloping, mosaic pattern, mucosal fissuring, or sporadically mucosal edema and aphthous ulceration, which are primarily limited to the proximal small bowel. [12]

Other laboratory abnormalities such as elevated hepatic transaminases, 67% of patients, mild immune-globulin deficiencies of IgG, IgM, or IgA in 33%, and vitamin deficiencies in 90%. [12]

Antibodies such as anti-smooth muscle antibodies, anti-liver/kidney microsomal antibodies, and the antinuclear antibody are sometimes positive however, this may be due to comorbid autoimmune disorders as appose to autoimmune enteropathy. [54] The presence of anti-goblet or anti-enterocyte cell antibodies raises the likelihood of autoimmune enteropathy, but are sometimes not present and are therefore not requires to establish diagnosis. [55]

Differential diagnosis

Autoimmune enteropathy and CVID share a number of characteristics, which can complicate diagnosis. [5] Features found in both disorders include crypt destruction and villous atrophy. [56] When doing a biopsy, plasma cell loss can aid in differentiating between the two conditions because, although plasma cells may not be present in CVID, autoimmune enteropathy is frequently characterized by a high number of plasma cells. [6]

Based on histologic findings the differential diagnosis of pediatric autoimmune enteropathy is graft-versus-host disease, Crohn's disease, and food sensitivity enteropathies such as celiac disease and lactose intolerance. [6]

Lactose intolerance should be excluded in infants with intractable diarrhea. Like autoimmune enteropathy, lactose intolerance can affect the whole GI tract with primary findings in the small bowel. Biopsy reveals prominent mononuclear cell infiltrate of the lamina propria, reveal flattened villi, and edema. Unlike autoimmune enteropathy, lactose intolerance is often characterized by absent crypt apoptosis and increased eosinophils. [6]

There are similarities between Crohn's disease and autoimmune enteropathy concerning their clinical and pathological presentations. However, rather than a lymphoplasmacytic infiltrate, the mucosal injury associated with Crohn's disease is more frequently accompanied by acute inflammation. Granulomas additionally support the diagnosis of Crohn's disease. [6]

There is no difference between autoimmune enteropathy and graft-versus-host disease when it comes to apoptosis. Correlation with the patient's clinical history is crucial in this situation. [6]

Treatment

Many patients with autoimmune enteropathy develop malnutrition. Oral nutritional supplements may help manage malnutrition however parenteral nutrition is often required. [7] Corticosteroids such as prednisone and budesonide are often the first line of treatment. In those who do not respond to corticosteroids immunosuppressive drugs such as infliximab, [57] tacrolimus, [58] 6-mercaptopurine, [59] sirolimus, [60] azathioprine, mycophenolate mofetil, rituximab, and cyclosporine have been used. [9] These medications have also been used alongside corticosteroids as maintenance therapy. These medications often have adverse side effects and don't always help maintain remission. [7]

Mesenchymal stem cell therapy has also been used to treat autoimmune enteropathy and has been shown to be curative. [3]

Outlook

Without treatment mortality rates of autoimmune enteropathy are as high as 30%. [8] Many factors such as the need for parenteral nutrition, [61] age of presentation, and the severity of symptoms can impact long-term outcomes. [3] No one treatment has been proven successful in all cases and relapses are common. [4]

Epidemiology

Autoimmune enteropathy is estimated to occur in less than 1 in 100,000 infants. [1]

There has been an increasing amount of adult-onset autoimmune enteropathy. The median age of diagnosis is 55 years old in adults with autoimmune enteropathy. 87% of these patients were white and there seems to be an equal distribution of females and males. [12]

See also

Related Research Articles

Immunodeficiency, also known as immunocompromisation, is a state in which the immune system's ability to fight infectious diseases and cancer is compromised or entirely absent. Most cases are acquired ("secondary") due to extrinsic factors that affect the patient's immune system. Examples of these extrinsic factors include HIV infection and environmental factors, such as nutrition. Immunocompromisation may also be due to genetic diseases/flaws such as SCID.

<span class="mw-page-title-main">Autoimmune polyendocrine syndrome</span> Medical condition

Autoimmune polyendocrine syndromes (APSs), also called polyglandular autoimmune syndromes (PGASs) or polyendocrine autoimmune syndromes (PASs), are a heterogeneous group of rare diseases characterized by autoimmune activity against more than one endocrine organ, although non-endocrine organs can be affected. There are three types of APS, and there are a number of other diseases which involve endocrine autoimmunity.

<span class="mw-page-title-main">Hashimoto's thyroiditis</span> Autoimmune disease

Hashimoto's thyroiditis, also known as chronic lymphocytic thyroiditis and Hashimoto's disease, is an autoimmune disease in which the thyroid gland is gradually destroyed. A slightly broader term is autoimmune thyroiditis, identical other than that it is also used to describe a similar condition without a goiter.

The regulatory T cells (Tregs or Treg cells), formerly known as suppressor T cells, are a subpopulation of T cells that modulate the immune system, maintain tolerance to self-antigens, and prevent autoimmune disease. Treg cells are immunosuppressive and generally suppress or downregulate induction and proliferation of effector T cells. Treg cells express the biomarkers CD4, FOXP3, and CD25 and are thought to be derived from the same lineage as naïve CD4+ cells. Because effector T cells also express CD4 and CD25, Treg cells are very difficult to effectively discern from effector CD4+, making them difficult to study. Research has found that the cytokine transforming growth factor beta (TGF-β) is essential for Treg cells to differentiate from naïve CD4+ cells and is important in maintaining Treg cell homeostasis.

<span class="mw-page-title-main">FOXP3</span> Immune response protein

FOXP3, also known as scurfin, is a protein involved in immune system responses. A member of the FOX protein family, FOXP3 appears to function as a master regulator of the regulatory pathway in the development and function of regulatory T cells. Regulatory T cells generally turn the immune response down. In cancer, an excess of regulatory T cell activity can prevent the immune system from destroying cancer cells. In autoimmune disease, a deficiency of regulatory T cell activity can allow other autoimmune cells to attack the body's own tissues.

<span class="mw-page-title-main">Cytotoxic T-lymphocyte associated protein 4</span> Mammalian protein found in humans

Cytotoxic T-lymphocyte associated protein 4, (CTLA-4) also known as CD152, is a protein receptor that functions as an immune checkpoint and downregulates immune responses. CTLA-4 is constitutively expressed in regulatory T cells but only upregulated in conventional T cells after activation – a phenomenon which is particularly notable in cancers. It acts as an "off" switch when bound to CD80 or CD86 on the surface of antigen-presenting cells. It is encoded by the gene CTLA4 in humans.

Common variable immunodeficiency (CVID) is an inborn immune disorder characterized by recurrent infections and low antibody levels, specifically in immunoglobulin (Ig) types IgG, IgM, and IgA. Symptoms generally include high susceptibility to pathogens, chronic lung disease, as well as inflammation and infection of the gastrointestinal tract.

<span class="mw-page-title-main">IPEX syndrome</span> Medical condition

Immunodysregulation polyendocrinopathy enteropathy X-linked syndrome is a rare autoimmune disease. It is one of the autoimmune polyendocrine syndromes. Most often, IPEX presents with autoimmune enteropathy, dermatitis (eczema), and autoimmune endocrinopathy, but other presentations exist.

Immune tolerance, also known as immunological tolerance or immunotolerance, refers to the immune system's state of unresponsiveness to substances or tissues that would otherwise trigger an immune response. It arises from prior exposure to a specific antigen and contrasts the immune system's conventional role in eliminating foreign antigens. Depending on the site of induction, tolerance is categorized as either central tolerance, occurring in the thymus and bone marrow, or peripheral tolerance, taking place in other tissues and lymph nodes. Although the mechanisms establishing central and peripheral tolerance differ, their outcomes are analogous, ensuring immune system modulation.

Immune dysregulation is any proposed or confirmed breakdown or maladaptive change in molecular control of immune system processes. For example, dysregulation is a component in the pathogenesis of autoimmune diseases and some cancers. Immune system dysfunction, as seen in IPEX syndrome leads to immune dysfunction, polyendocrinopathy, enteropathy, X-linked (IPEX). IPEX typically presents during the first few months of life with diabetes mellitus, intractable diarrhea, failure to thrive, eczema, and hemolytic anemia. unrestrained or unregulated immune response.

<span class="mw-page-title-main">IL2RA</span> Mammalian protein found in Homo sapiens

The Interleukin-2 receptor alpha chain is a protein involved in the assembly of the high-affinity Interleukin-2 receptor, consisting of alpha (IL2RA), beta (IL2RB) and the common gamma chain (IL2RG). As the name indicates, this receptor interacts with Interleukin-2, a pleiotropic cytokine which plays an important role in immune homeostasis.

Congenital hypoplastic anemia is a congenital disorder that occasionally also includes leukopenia and thrombocytopenia and is characterized by deficiencies of red cell precursors.

<span class="mw-page-title-main">Autoimmune polyendocrine syndrome type 1</span> Autoimmune condition causing dysfunction of endocrine glands

Autoimmune polyendocrine syndrome type 1 (APS-1), is a subtype of autoimmune polyendocrine syndrome. It causes the dysfunction of multiple endocrine glands due to autoimmunity. It is a genetic disorder, inherited in autosomal recessive fashion due to a defect in the AIRE gene , which is located on chromosome 21 and normally confers immune tolerance.

<span class="mw-page-title-main">CD25 deficiency</span> Medical condition

CD25 deficiency or interleukin 2 receptor alpha deficiency is an immunodeficiency disorder associated with mutations in the interleukin 2 receptor alpha (CD25) (IL2RA) gene. The mutations cause expression of a defective α chain or complete absence thereof, an essential part of high-affinity interleukin-2 (IL-2) receptors. The result is a syndrome described as IPEX-like or a SCID.

STAT3 gain-of function (GOF) is a rare genetic disorder of the immune system, leading to early-onset autoimmunity and a variety of multi-organ disorders. The condition is progressive and manifests through a broad spectrum of clinical symptoms, including lymphadenopathy, autoimmune cytopenias, growth delays, enteropathy, lung disease, endocrine disorders, arthritis, autoimmune hepatitis, neurological diseases, vasculopathy, eczema, infections, and multiorgan autoimmunity. Patients experience recurring infections.

<span class="mw-page-title-main">LRBA deficiency</span> Medical condition

LRBA deficiency is a rare genetic disorder of the immune system. This disorder is caused by a mutation in the gene LRBA. LRBA stands for “lipopolysaccharide (LPS)-responsive and beige-like anchor protein”. This condition is characterized by autoimmunity, lymphoproliferation, and immune deficiency. It was first described by Gabriela Lopez-Herrera from University College London in 2012. Investigators in the laboratory of Dr. Michael Lenardo at National Institute of Allergy and Infectious Diseases, the National Institutes of Health and Dr. Michael Jordan at Cincinnati Children’s Hospital Medical Center later described this condition and therapy in 2015.

CHAI disease is a rare genetic disorder of the immune system that illustrates the role of CTLA-4 in cell signaling. CHAI stands for “Autoimmune lymphoproliferative syndrome due to CTLA4 haplo-insufficiency.” The disease is characterized by variable combination of enteropathy, hypogammaglobulinemia, recurrent respiratory infections, granulomatous lymphocytic interstitial lung disease, lymphocytic infiltration of non-lymphoid organs, autoimmune thrombocytopenia or neutropenia, autoimmune hemolytic anemia and lymphadenopathy. It is closely linked to LATIAE disease. Investigators in the laboratory of Dr. Michael Lenardo, National Institute of Allergy and Infectious Diseases at the National Institutes of Health first described this condition in 2018.

Autoinflammatory diseases (AIDs) are a group of rare disorders caused by dysfunction of the innate immune system. These responses are characterized by periodic or chronic systemic inflammation, usually without the involvement of adaptive immunity.

<span class="mw-page-title-main">Congenital athymia</span> Rare immune disorder where the thymus is missing at birth

Congenital athymia is an extremely rare disorder marked by the absence of the thymus at birth. T cell maturation and selection depend on the thymus, and newborns born without a thymus experience severe immunodeficiency. A significant T cell deficiency, recurrent infections, susceptibility to opportunistic infections, and a tendency to develop autologous graft-versus-host disease (GVHD) or, in the case of complete DiGeorge syndrome, a "atypical" phenotype are characteristics of congenital athymia.

References

  1. 1 2 3 4 5 6 7 8 Montalto, Massimo; D'Onofrio, Ferruccio; Santoro, Luca; Gallo, Antonella; Gasbarrini, Antonio; Gasbarrini, Giovanni (2009). "Autoimmune enteropathy in children and adults". Scandinavian Journal of Gastroenterology. 44 (9). Informa UK Limited: 1029–1036. doi:10.1080/00365520902783691. ISSN   0036-5521. PMID   19255930. S2CID   33004674 . Retrieved December 1, 2023.
  2. 1 2 Ruemmele, Frank M.; Brousse, Nicole; Goulet, Olivier (2004). "Autoimmune enteropathy: molecular concepts". Current Opinion in Gastroenterology. 20 (6). Ovid Technologies (Wolters Kluwer Health): 587–591. doi:10.1097/00001574-200411000-00014. ISSN   0267-1379. PMID   15703687. S2CID   23128686 . Retrieved December 1, 2023.
  3. 1 2 3 4 5 Ahmed, Zunirah; Imdad, Aamer; Connelly, James A.; Acra, Sari (November 10, 2018). "Autoimmune Enteropathy: An Updated Review with Special Focus on Stem Cell Transplant Therapy". Digestive Diseases and Sciences. 64 (3). Springer Science and Business Media LLC: 643–654. doi: 10.1007/s10620-018-5364-1 . ISSN   0163-2116. PMC   8260026 . PMID   30415406.
  4. 1 2 Umetsu, Sarah E.; Brown, Ian; Langner, Cord; Lauwers, Gregory Y. (October 11, 2017). "Autoimmune enteropathies". Virchows Archiv. 472 (1). Springer Science and Business Media LLC: 55–66. doi:10.1007/s00428-017-2243-7. ISSN   0945-6317. S2CID   3905594 . Retrieved December 1, 2023.
  5. 1 2 3 4 5 6 Chen, Charles B.; Tahboub, Farah; Plesec, Thomas; Kay, Marsha; Radhakrishnan, Kadakkal (August 24, 2020). "A Review of Autoimmune Enteropathy and Its Associated Syndromes". Digestive Diseases and Sciences. 65 (11). Springer Science and Business Media LLC: 3079–3090. doi:10.1007/s10620-020-06540-8. ISSN   0163-2116. PMID   32833153. S2CID   221257881 . Retrieved December 1, 2023.
  6. 1 2 3 4 5 6 Singhi, Aatur D; Goyal, Alka; Davison, Jon M; Regueiro, Miguel D; Roche, Robyn L; Ranganathan, Sarangarajan (2014). "Pediatric autoimmune enteropathy: an entity frequently associated with immunodeficiency disorders". Modern Pathology. 27 (4). Elsevier BV: 543–553. doi: 10.1038/modpathol.2013.150 . ISSN   0893-3952.
  7. 1 2 3 4 5 Blanco Quirós, A.; Arranz Sanz, E.; Bernardo Ordiz, D.; Garrote Adrados, J.A. (2009). "From autoimmune enteropathy to the IPEX (immune dysfunction, polyendocrinopathy, enteropathy, X-linked) syndrome". Allergologia et Immunopathologia. 37 (4). Codon Publications: 208–215. doi:10.1016/j.aller.2009.04.002. ISSN   0301-0546. PMID   19912978 . Retrieved December 1, 2023.
  8. 1 2 Seidman, Ernest G.; Lacaille, Florence; Russo, Pierre; Galeano, Narmer; Murphy, Gerard; Roy, Claude C. (1990). "Successful treatment of autoimmune enteropathy with cyclosporine". The Journal of Pediatrics. 117 (6). Elsevier BV: 929–932. doi:10.1016/s0022-3476(05)80140-4. ISSN   0022-3476. PMID   2246696 . Retrieved December 1, 2023.
  9. 1 2 3 Biagi, F; Corazza, GR (1997). "Autoimmune enteropathy in adults". The Lancet. 350 (9082). Elsevier BV: 960. doi: 10.1016/s0140-6736(05)63302-8 . ISSN   0140-6736.
  10. ↑ WALKERSMITH, J (1982). "Autoantibodies Against Gut Epithelium in Child with Small-Intestinal Enteropathy". The Lancet. 319 (8271). Elsevier BV: 566–567. doi:10.1016/s0140-6736(82)92076-1. ISSN   0140-6736. PMID   6120421. S2CID   26473878 . Retrieved December 1, 2023.
  11. ↑ Sakaguchi, Shimon (March 22, 2005). "Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and non-self". Nature Immunology. 6 (4). Springer Science and Business Media LLC: 345–352. doi:10.1038/ni1178. ISSN   1529-2908. PMID   15785760. S2CID   14683763 . Retrieved December 1, 2023.
  12. 1 2 3 4 5 6 Akram, Salma; Murray, Joseph A.; Pardi, Darrell S.; Alexander, Glenn L.; Schaffner, John A.; Russo, Pierre A.; Abraham, Susan C. (2007). "Adult Autoimmune Enteropathy: Mayo Clinic Rochester Experience". Clinical Gastroenterology and Hepatology. 5 (11). Elsevier BV: 1282–1290. doi: 10.1016/j.cgh.2007.05.013 . ISSN   1542-3565. PMC   2128725 . PMID   17683994.
  13. ↑ Hill, S M; Milla, P J; Bottazzo, G F; Mirakian, R (January 1, 1991). "Autoimmune enteropathy and colitis: is there a generalised autoimmune gut disorder?". Gut. BMJ. 32 (1): 36–42. doi: 10.1136/gut.32.1.36 . ISSN   0017-5749. PMC   1379210 . PMID   1991636.
  14. ↑ Cuenod, Bana; Brousse, Nicole; Goulet, Olivier; De Potter, Sophie; Mougenot, Jean-François; Ricour, Claude; Guy-Grand, Delphine; Cerf-Bensussan, Nadine (1990). "Classification of intractable diarrhea in infancy using clinical and immunohistological criteria". Gastroenterology. 99 (4). Elsevier BV: 1037–1043. doi:10.1016/0016-5085(90)90624-a. ISSN   0016-5085. PMID   2203660 . Retrieved December 1, 2023.
  15. ↑ Shihaz, Ambalathu Veettil Hussain; Paul, Jayanta (October 19, 2020). "Autoimmune enteropathy in <scp>adults</scp>". Advances in Digestive Medicine. 9 (2). Wiley: 75–81. doi: 10.1002/aid2.13234 . ISSN   2351-9797.
  16. ↑ Carroccio, Antonio; Volta, Umberto; Di Prima, Lidia; Petrolini, Nunzio; Florena, Ada Maria; Averna, Maurizio R.; Montalto, Giuseppe; Notarbartolo, Alberto (2003). "CASE REPORT: Autoimmune Enteropathy and Colitis in an Adult Patient". Digestive Diseases and Sciences. 48 (8). Springer Science and Business Media LLC: 1600–1606. doi:10.1023/a:1024705032326. ISSN   0163-2116. PMID   12924654. S2CID   12286028 . Retrieved December 1, 2023.
  17. 1 2 Russo, Pierre A.; Brochu, Pierre; Seidman, Ernest G.; Roy, Claude C. (1999). "Autoimmune Enteropathy". Pediatric and Developmental Pathology. 2 (1). SAGE Publications: 65–71. doi:10.1007/s100249900092. ISSN   1093-5266. PMID   9841709. S2CID   40692057 . Retrieved December 1, 2023.
  18. 1 2 Lachaux, A (1996). "L'entéropathie auto-immune". Archives de Pédiatrie (in French). 3 (3). Elsevier BV: 261–266. doi:10.1016/0929-693x(96)81306-6. ISSN   0929-693X. PMID   8785566 . Retrieved December 1, 2023.
  19. ↑ VOLTA, U; DEANGELIS, G; GRANITO, A; PETROLINI, N; FIORINI, E; GUIDI, M; MURATORI, P; BIANCHI, F (2006). "Autoimmune enteropathy and rheumatoid arthritis: A new association in the field of autoimmunity". Digestive and Liver Disease. 38 (12). Elsevier BV: 926–929. doi:10.1016/j.dld.2006.02.003. ISSN   1590-8658. PMID   16920048 . Retrieved December 1, 2023.
  20. ↑ Mais, Daniel D.; Mulhall, Brian P.; Adolphson, Kimberly R.; Yamamoto, Kazunori (December 1, 1999). "Thymoma-Associated Autoimmune Enteropathy: A Report of Two Cases". American Journal of Clinical Pathology. 112 (6). Oxford University Press (OUP): 810–815. doi: 10.1093/ajcp/112.6.810 . ISSN   0002-9173. PMID   10587704.
  21. ↑ Barzaghi, Federica; Passerini, Laura; Bacchetta, Rosa (2012). "Immune Dysregulation, Polyendocrinopathy, Enteropathy, X-Linked Syndrome: A Paradigm of Immunodeficiency with Autoimmunity". Frontiers in Immunology. 3. Frontiers Media SA: 211. doi: 10.3389/fimmu.2012.00211 . ISSN   1664-3224. PMC   3459184 . PMID   23060872.
  22. ↑ Kadakia, Sejal; Farnaes, Lauge; Dimmock, David; Chowdhury, Shimul; Ding, Yan; Anderson, Eric J.; Kingsmore, Stephen; Newfield, Ron S. (September 27, 2019). "Diagnosis and treatment of a boy with IPEX syndrome presenting with diabetes in early infancy". Clinical Case Reports. 7 (11). Wiley: 2123–2127. doi: 10.1002/ccr3.2438 . ISSN   2050-0904. PMC   6878034 . PMID   31788263.
  23. 1 2 Husebye, E. S.; Perheentupa, J.; Rautemaa, R.; Kämpe, O. (April 6, 2009). "Clinical manifestations and management of patients with autoimmune polyendocrine syndrome type I". Journal of Internal Medicine. 265 (5). Wiley: 514–529. doi: 10.1111/j.1365-2796.2009.02090.x . ISSN   0954-6820. PMID   19382991.
  24. ↑ van der Vliet, Hans J. J.; Nieuwenhuis, Edward E. (2007). "IPEX as a Result of Mutations in FOXP3". Clinical and Developmental Immunology. 2007. Hindawi Limited: 1–5. doi: 10.1155/2007/89017 . ISSN   1740-2522. PMC   2248278 . PMID   18317533.
  25. ↑ Yagi, Haruhiko; Nomura, Takashi; Nakamura, Kyoko; Yamazaki, Sayuri; Kitawaki, Toshio; Hori, Shohei; Maeda, Michiyuki; Onodera, Masafumi; Uchiyama, Takashi; Fujii, Shingo; Sakaguchi, Shimon (October 4, 2004). "Crucial role of FOXP3 in the development and function of human CD25+CD4+ regulatory T cells". International Immunology. 16 (11). Oxford University Press (OUP): 1643–1656. doi:10.1093/intimm/dxh165. hdl: 2433/144729 . ISSN   1460-2377. PMID   15466453 . Retrieved December 1, 2023.
  26. ↑ Ben-Skowronek, Iwona (February 24, 2021). "IPEX Syndrome: Genetics and Treatment Options". Genes. 12 (3). MDPI AG: 323. doi: 10.3390/genes12030323 . ISSN   2073-4425. PMC   7995986 . PMID   33668198.
  27. 1 2 Murguia-Favela, Luis; Hong-Diep Kim, Vy; Upton, Julia; Thorner, Paul; Reid, Brenda; Atkinson, Adelle; Grunebaum, Eyal (March 1, 2015). "IPEX syndrome caused by a novel mutation in FOXP3 gene can be cured by bone marrow transplantation from an unrelated donor after myeloablative conditioning". LymphoSign Journal. 2 (1). LymphoSign Journal Limited Partnership: 31–38. doi: 10.14785/lpsn-2014-0016 . ISSN   2292-5937.
  28. ↑ Bacchetta, Rosa; Barzaghi, Federica; Roncarolo, Maria-Grazia (February 25, 2016). "From IPEX syndrome to FOXP3 mutation: a lesson on immune dysregulation". Annals of the New York Academy of Sciences. 1417 (1). Wiley: 5–22. doi: 10.1111/nyas.13011 . ISSN   0077-8923. PMID   26918796.
  29. ↑ Seidel, Markus G.; Boztug, Kaan; Haas, Oskar A. (December 10, 2015). "Immune Dysregulation Syndromes (IPEX, CD27 Deficiency, and Others): Always Doomed from the Start?". Journal of Clinical Immunology. 36 (1). Springer Science and Business Media LLC: 6–7. doi:10.1007/s10875-015-0218-5. ISSN   0271-9142. PMID   26661331. S2CID   14591061 . Retrieved December 1, 2023.
  30. 1 2 Gambineri, Eleonora; Ciullini Mannurita, Sara; Hagin, David; Vignoli, Marina; Anover-Sombke, Stephanie; DeBoer, Stacey; Segundo, Gesmar R. S.; Allenspach, Eric J.; Favre, Claudio; Ochs, Hans D.; Torgerson, Troy R. (November 1, 2018). "Clinical, Immunological, and Molecular Heterogeneity of 173 Patients With the Phenotype of Immune Dysregulation, Polyendocrinopathy, Enteropathy, X-Linked (IPEX) Syndrome". Frontiers in Immunology. 9. Frontiers Media SA: 2411. doi: 10.3389/fimmu.2018.02411 . ISSN   1664-3224. PMC   6223101 . PMID   30443250.
  31. ↑ Barzaghi, Federica; Amaya Hernandez, Laura Cristina; Neven, Benedicte; Ricci, Silvia; Kucuk, Zeynep Yesim; Bleesing, Jack J.; Nademi, Zohreh; Slatter, Mary Anne; Ulloa, Erlinda Rose; Shcherbina, Anna; Roppelt, Anna; Worth, Austen; Silva, Juliana; Aiuti, Alessandro; Murguia-Favela, Luis; Speckmann, Carsten; Carneiro-Sampaio, Magda; Fernandes, Juliana Folloni; Baris, Safa; Ozen, Ahmet; Karakoc-Aydiner, Elif; Kiykim, Ayca; Schulz, Ansgar; Steinmann, Sandra; Notarangelo, Lucia Dora; Gambineri, Eleonora; Lionetti, Paolo; Shearer, William Thomas; Forbes, Lisa R.; Martinez, Caridad; Moshous, Despina; Blanche, Stephane; Fisher, Alain; Ruemmele, Frank M.; Tissandier, Come; Ouachee-Chardin, Marie; Rieux-Laucat, Frédéric; Cavazzana, Marina; Qasim, Waseem; Lucarelli, Barbarella; Albert, Michael H.; Kobayashi, Ichiro; Alonso, Laura; Diaz De Heredia, Cristina; Kanegane, Hirokazu; Lawitschka, Anita; Seo, Jong Jin; Gonzalez-Vicent, Marta; Diaz, Miguel Angel; Goyal, Rakesh Kumar; Sauer, Martin G.; Yesilipek, Akif; Kim, Minsoo; Yilmaz-Demirdag, Yesim; Bhatia, Monica; Khlevner, Julie; Richmond Padilla, Erick J.; Martino, Silvana; Montin, Davide; Neth, Olaf; Molinos-Quintana, Agueda; Valverde-Fernandez, Justo; Broides, Arnon; Pinsk, Vered; Ballauf, Antje; Haerynck, Filomeen; Bordon, Victoria; Dhooge, Catharina; Garcia-Lloret, Maria Laura; Bredius, Robbert G.; Kałwak, Krzysztof; Haddad, Elie; Seidel, Markus Gerhard; Duckers, Gregor; Pai, Sung-Yun; Dvorak, Christopher C.; Ehl, Stephan; Locatelli, Franco; Goldman, Frederick; Gennery, Andrew Richard; Cowan, Mort J.; Roncarolo, Maria-Grazia; Bacchetta, Rosa (2018). "Long-term follow-up of IPEX syndrome patients after different therapeutic strategies: An international multicenter retrospective study". Journal of Allergy and Clinical Immunology. 141 (3). Elsevier BV: 1036–1049.e5. doi: 10.1016/j.jaci.2017.10.041 . hdl: 1854/LU-8559319 . ISSN   0091-6749. PMC   6050203 . PMID   29241729.
  32. ↑ Barker, Jennifer M.; Anderson, Mark S.; Gottlieb, Peter A. (2016). "The Immunoendocrinopathy Syndromes". Williams Textbook of Endocrinology. Elsevier. pp. 1762–1775. doi:10.1016/b978-0-323-29738-7.00040-x. ISBN   978-0-323-29738-7 . Retrieved December 1, 2023.
  33. ↑ Charbonnier, Louis-Marie; Janssen, Erin; Chou, Janet; Ohsumi, Toshiro K.; Keles, Sevgi; Hsu, Joyce T.; Massaad, Michel J.; Garcia-Lloret, Maria; Hanna-Wakim, Rima; Dbaibo, Ghassan; Alangari, Abdullah A.; Alsultan, Abdulrahman; Al-Zahrani, Daifulah; Geha, Raif S.; Chatila, Talal A. (2015). "Regulatory T-cell deficiency and immune dysregulation, polyendocrinopathy, enteropathy, X-linked–like disorder caused by loss-of-function mutations in LRBA". Journal of Allergy and Clinical Immunology. 135 (1). Elsevier BV: 217–227.e9. doi: 10.1016/j.jaci.2014.10.019 . ISSN   0091-6749. PMC   4289093 . PMID   25468195.
  34. ↑ Vignoli, Marina; Ciullini Mannurita, Sara; Fioravanti, Antonella; Tumino, Manuela; Grassi, Alessia; Guariso, Graziella; Favre, Claudio; D'Elios, Mario M.; Gambineri, Eleonora (2019). "CD25 deficiency: A new conformational mutation prevents the receptor expression on cell surface". Clinical Immunology. 201. Elsevier BV: 15–19. doi:10.1016/j.clim.2019.02.003. hdl: 2158/1161038 . ISSN   1521-6616. PMID   30742970. S2CID   73427287 . Retrieved December 1, 2023.
  35. ↑ Tivol, Elizabeth A.; Gorski, Jack (August 15, 2002). "Re-establishing Peripheral Tolerance in the Absence of CTLA-4: Complementation by Wild-Type T Cells Points to an Indirect Role for CTLA-4". The Journal of Immunology. 169 (4). The American Association of Immunologists: 1852–1858. doi: 10.4049/jimmunol.169.4.1852 . ISSN   0022-1767. PMID   12165509.
  36. ↑ Eren Akarcan, Sanem; Edeer Karaca, Neslihan; Aksu, Guzide; Aykut, Ayca; Yilmaz Karapinar, Deniz; Cetin, Funda; Aydinok, Yesim; Azarsiz, Elif; Gambineri, Eleonora; Cogulu, Ozgur; Ulusoy Severcan, Ezgi; Alper, Hudaver; Kutukculer, Necil (October 1, 2018). "Two male siblings with a novel LRBA mutation presenting with different findings of IPEX syndrome". JMM Case Reports. 5 (10). Microbiology Society: e005167. doi: 10.1099/jmmcr.0.005167 . ISSN   2053-3721. PMC   6249428 . PMID   30479781.
  37. ↑ Lopez-Herrera, Gabriela; Tampella, Giacomo; Pan-Hammarström, Qiang; Herholz, Peer; Trujillo-Vargas, Claudia M.; Phadwal, Kanchan; Simon, Anna Katharina; Moutschen, Michel; Etzioni, Amos; Mory, Adi; Srugo, Izhak; Melamed, Doron; Hultenby, Kjell; Liu, Chonghai; Baronio, Manuela; Vitali, Massimiliano; Philippet, Pierre; Dideberg, Vinciane; Aghamohammadi, Asghar; Rezaei, Nima; Enright, Victoria; Du, Likun; Salzer, Ulrich; Eibel, Hermann; Pfeifer, Dietmar; Veelken, Hendrik; Stauss, Hans; Lougaris, Vassilios; Plebani, Alessandro; Gertz, E. Michael; Schäffer, Alejandro A.; Hammarström, Lennart; Grimbacher, Bodo (8 June 2012). "Deleterious Mutations in LRBA Are Associated with a Syndrome of Immune Deficiency and Autoimmunity". American Journal of Human Genetics. 90 (6): 986–1001. doi: 10.1016/j.ajhg.2012.04.015 . ISSN   0002-9297. PMC   3370280 . PMID   22608502.
  38. ↑ Hou, Tie Zheng; Verma, Nisha; Wanders, Jennifer; Kennedy, Alan; Soskic, Blagoje; Janman, Daniel; Halliday, Neil; Rowshanravan, Behzad; Worth, Austen; Qasim, Waseem; Baxendale, Helen; Stauss, Hans; Seneviratne, Suranjith; Neth, Olaf; Olbrich, Peter; Hambleton, Sophie; Arkwright, Peter D.; Burns, Siobhan O.; Walker, Lucy S. K.; Sansom, David M. (March 16, 2017). "Identifying functional defects in patients with immune dysregulation due to LRBA and CTLA-4 mutations". Blood. 129 (11). American Society of Hematology: 1458–1468. doi: 10.1182/blood-2016-10-745174 . ISSN   0006-4971. PMC   5438243 . PMID   28159733.
  39. ↑ Schubert, Desirée; Bode, Claudia; Kenefeck, Rupert; Hou, Tie Zheng; Wing, James B; Kennedy, Alan; Bulashevska, Alla; Petersen, Britt-Sabina; Schäffer, Alejandro A; Grüning, Björn A; Unger, Susanne; Frede, Natalie; Baumann, Ulrich; Witte, Torsten; Schmidt, Reinhold E; Dueckers, Gregor; Niehues, Tim; Seneviratne, Suranjith; Kanariou, Maria; Speckmann, Carsten; Ehl, Stephan; Rensing-Ehl, Anne; Warnatz, Klaus; Rakhmanov, Mirzokhid; Thimme, Robert; Hasselblatt, Peter; Emmerich, Florian; Cathomen, Toni; Backofen, Rolf; Fisch, Paul; Seidl, Maximilian; May, Annette; Schmitt-Graeff, Annette; Ikemizu, Shinji; Salzer, Ulrich; Franke, Andre; Sakaguchi, Shimon; Walker, Lucy S K; Sansom, David M; Grimbacher, Bodo (October 20, 2014). "Autosomal dominant immune dysregulation syndrome in humans with CTLA4 mutations". Nature Medicine. 20 (12). Springer Science and Business Media LLC: 1410–1416. doi: 10.1038/nm.3746 . ISSN   1078-8956. PMC   4668597 . PMID   25329329.
  40. ↑ Kucuk, Zeynep Yesim; Charbonnier, Louis-Marie; McMasters, Richard L.; Chatila, Talal; Bleesing, Jack J. (2017). "CTLA-4 haploinsufficiency in a patient with an autoimmune lymphoproliferative disorder". Journal of Allergy and Clinical Immunology. 140 (3). Elsevier BV: 862–864.e4. doi: 10.1016/j.jaci.2017.02.032 . ISSN   0091-6749. PMC   5591763 . PMID   28366794.
  41. ↑ Lo, Bernice; Fritz, Jill M.; Su, Helen C.; Uzel, Gulbu; Jordan, Michael B.; Lenardo, Michael J. (August 25, 2016). "CHAI and LATAIE: new genetic diseases of CTLA-4 checkpoint insufficiency". Blood. 128 (8). American Society of Hematology: 1037–1042. doi: 10.1182/blood-2016-04-712612 . ISSN   0006-4971. PMC   5000841 . PMID   27418640.
  42. ↑ Cohen, Aileen C.; Nadeau, Kari C.; Tu, Wenwei; Hwa, Vivian; Dionis, Kira; Bezrodnik, Liliana; Teper, Alejandro; Gaillard, Maria; Heinrich, Juan; Krensky, Alan M.; Rosenfeld, Ron G.; Lewis, David B. (September 1, 2006). "Cutting Edge: Decreased Accumulation and Regulatory Function of CD4+CD25high T Cells in Human STAT5b Deficiency". The Journal of Immunology. 177 (5). The American Association of Immunologists: 2770–2774. doi: 10.4049/jimmunol.177.5.2770 . ISSN   0022-1767. PMID   16920911 . Retrieved December 1, 2023.
  43. ↑ Bernasconi, Andrea; Marino, Roxana; Ribas, Alejandra; Rossi, Jorge; Ciaccio, Marta; Oleastro, Matías; Ornani, Alicia; Paz, Rubén; Rivarola, Marco A.; Zelazko, Marta; Belgorosky, Alicia (November 1, 2006). "Characterization of Immunodeficiency in a Patient With Growth Hormone Insensitivity Secondary to a Novel STAT5b Gene Mutation". Pediatrics. 118 (5). American Academy of Pediatrics (AAP): e1584–e1592. doi:10.1542/peds.2005-2882. ISSN   0031-4005. PMID   17030597. S2CID   28123490 . Retrieved December 1, 2023.
  44. ↑ Lohr, Naomi J.; Molleston, Jean P.; Strauss, Kevin A.; Torres-Martinez, Wilfredo; Sherman, Eric A.; Squires, Robert H.; Rider, Nicholas L.; Chikwava, Kudakwashe R.; Cummings, Oscar W.; Morton, D. Holmes; Puffenberger, Erik G. (2010). "Human ITCH E3 Ubiquitin Ligase Deficiency Causes Syndromic Multisystem Autoimmune Disease". The American Journal of Human Genetics. 86 (3). Elsevier BV: 447–453. doi: 10.1016/j.ajhg.2010.01.028 . ISSN   0002-9297. PMC   2833372 . PMID   20170897.
  45. ↑ Bruserud, Øyvind; Oftedal, Bergithe E; Wolff, Anette B; Husebye, Eystein S (2016). "AIRE-mutations and autoimmune disease". Current Opinion in Immunology. 43. Elsevier BV: 8–15. doi:10.1016/j.coi.2016.07.003. ISSN   0952-7915. PMID   27504588 . Retrieved December 1, 2023.
  46. ↑ Kahaly, G. J.; Frommer, L. (August 17, 2017). "Polyglandular autoimmune syndromes". Journal of Endocrinological Investigation. 41 (1). Springer Science and Business Media LLC: 91–98. doi:10.1007/s40618-017-0740-9. ISSN   1720-8386. PMID   28819917. S2CID   13428315 . Retrieved December 1, 2023.
  47. ↑ Unsworth, D. J.; Walker-Smith, J. A. (1985). "Autoimmunity in Diarrhoeal Disease". Journal of Pediatric Gastroenterology and Nutrition. 4 (3). Ovid Technologies (Wolters Kluwer Health): 375–380. doi: 10.1097/00005176-198506000-00009 . ISSN   0277-2116. PMID   4020570.
  48. ↑ Villanacci, Vincenzo; Lougaris, Vassilios; Ravelli, Alberto; Buscarini, Elisabetta; Salviato, Tiziana; Lionetti, Paolo; Salemme, Marianna; Martelossi, Stefano; De Giacomo, Costantino; Falchetti, Diego; Pelizzo, Gloria; Bassotti, Gabrio (2019). "Clinical manifestations and gastrointestinal pathology in 40 patients with autoimmune enteropathy". Clinical Immunology. 207. Elsevier BV: 10–17. doi:10.1016/j.clim.2019.07.001. ISSN   1521-6616. PMID   31279857. S2CID   195830350 . Retrieved December 1, 2023.
  49. ↑ Hartfield, Dawn; Turner, Justine; Huynh, Hien; Lidman, Per; Chaba, Todd; Lacson, Atilano (2010). "The Role of Histopathology in Diagnosing Protracted Diarrhea of Infancy". Fetal and Pediatric Pathology. 29 (3). Informa UK Limited: 144–157. doi:10.3109/15513811003777300. ISSN   1551-3815. PMID   20450267. S2CID   42473363 . Retrieved December 1, 2023.
  50. ↑ Veress, B.; Franzén, L.; Bodin, L.; Borch, K. (2004). "Duodenal intraepithelial lymphocyte-count revisited". Scandinavian Journal of Gastroenterology. 39 (2). Informa UK Limited: 138–144. doi:10.1080/00365520310007675. ISSN   0036-5521. PMID   15000275. S2CID   5839786.
  51. ↑ Bishu, Shrinivas; Arsenescu, Violeta; Lee, Eun Y; Vargas, H David; de Villiers, Willem JS; Arsenescu, Razvan (November 29, 2011). "Autoimmune enteropathy with a CD8+ CD7-T-cell small bowel intraepithelial lymphocytosis: case report and literature review". BMC Gastroenterology. 11 (1). Springer Science and Business Media LLC: 131. doi: 10.1186/1471-230x-11-131 . ISSN   1471-230X. PMC   3287162 . PMID   22126605.
  52. ↑ Gram-Kampmann, Eva-Marie; Lillevang, Søren T; Detlefsen, Sönke; Laursen, Stig Borbjerg (July 6, 2015). "Wireless capsule endoscopy as a tool in diagnosing autoimmune enteropathy". BMJ Case Reports. BMJ. 2015: bcr2014207931. doi: 10.1136/bcr-2014-207931 . ISSN   1757-790X. PMC   4493217 . PMID   26150615.
  53. ↑ Masia, Ricard; Peyton, Stephen; Lauwers, Gregory Y.; Brown, Ian (2014). "Gastrointestinal Biopsy Findings of Autoimmune Enteropathy". American Journal of Surgical Pathology. 38 (10). Ovid Technologies (Wolters Kluwer Health): 1319–1329. doi: 10.1097/pas.0000000000000317 . ISSN   0147-5185. PMC   4162848 . PMID   25188868.
  54. ↑ Biagi, Federico; Bianchi, Paola I.; Trotta, Lucia; Corazza, Gino R. (2009). "Anti-Goblet Cell Antibodies for the Diagnosis of Autoimmune Enteropathy?". American Journal of Gastroenterology. 104 (12). Ovid Technologies (Wolters Kluwer Health): 3112. doi:10.1038/ajg.2009.511. ISSN   0002-9270. PMID   19956142. S2CID   52805844 . Retrieved December 1, 2023.
  55. ↑ Odetola, Oluwatobi; Ananthanarayanan, Vijayalakshmi (November 16, 2018). "Gastrointestinal Presentations of Common Variable Immunodeficiency: Hiding in Plain Sight". Archives of Pathology & Laboratory Medicine. 143 (4). Archives of Pathology and Laboratory Medicine: 525–530. doi: 10.5858/arpa.2017-0372-rs . ISSN   0003-9985. PMID   30444437.
  56. ↑ Elwing, Jill E.; Clouse, Ray E. (2005). "Adult-Onset Autoimmune Enteropathy in the Setting of Thymoma Successfully Treated with Infliximab". Digestive Diseases and Sciences. 50 (5). Springer Science and Business Media LLC: 928–932. doi:10.1007/s10620-005-2666-x. ISSN   0163-2116. PMID   15906770. S2CID   38664543 . Retrieved December 1, 2023.
  57. ↑ Daum, Severin; Sahin, Ergün; Jansen, Andreas; Heine, Bernhard; Riecken, Ernst-Otto; Zeitz, Martin; Schmidt, Wolfgang (2003). "Adult Autoimmune Enteropathy Treated Successfully with Tacrolimus". Digestion. 68 (2–3). S. Karger AG: 86–90. doi:10.1159/000074520. ISSN   0012-2823. PMID   14581765. S2CID   20837497 . Retrieved December 1, 2023.
  58. ↑ Miyazaki, Haruka; Hoshi, Namiko; Kohashi, Michitaka; Tokunaga, Eri; Ku, Yuna; Takenaka, Haruka; Ooi, Makoto; Yamamoto, Nobuyuki; Uemura, Suguru; Nishimura, Noriyuki; Iijima, Kazumoto; Jimbo, Keisuke; Okano, Tsubasa; Hoshino, Akihiro; Imai, Kohsuke; Kanegane, Hirokazu; Kobayashi, Ichiro; Kodama, Yuzo (January 30, 2022). "A case of autoimmune enteropathy with CTLA4 haploinsufficiency". Intestinal Research. 20 (1). Korean Association for the Study of Intestinal Diseases: 144–149. doi: 10.5217/ir.2020.00041 . hdl: 20.500.14094/90008958 . ISSN   1598-9100. PMC   8831778 . PMID   33476510.
  59. ↑ Azizi, G.; Abolhassani, H.; Yazdani, R.; Mohammadikhajehdehi, S.; Parvaneh, N.; Negahdari, B.; Mohammadi, J.; Aghamohammadi, A. (2017). "New therapeutic approach by sirolimus for enteropathy treatment in patients with LRBA deficiency". European Annals of Allergy and Clinical Immunology. 49 (5). Edra SpA: 235–239. doi: 10.23822/eurannaci.1764-1489.22 . ISSN   1764-1489. PMID   28884992.
  60. ↑ Gambarara, M.; Bracci, F.; Diamanti, A.; Ambrosini, M.I.; Pietrobattista, A.; Knafelz, D.; Ferretti, F.; Castro, M. (2005). "Long-Term Parenteral Nutrition in Pediatric Autoimmune Enteropathies". Transplantation Proceedings. 37 (5). Elsevier BV: 2270–2271. doi:10.1016/j.transproceed.2005.03.063. ISSN   0041-1345. PMID   15964396 . Retrieved December 1, 2023.

Further reading

This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.